Is Mounjaro in Stock in the UK? A Clear Look at Availability and Supply

Short answer: yes, for most people, most of the time. As of mid-2026 Mounjaro (tirzepatide) is far more reliably available across UK pharmacies than it was during the acute shortages of 2023 and 2024. Manufacturing has scaled up, the KwikPen multi-dose device has settled in, and the days of refreshing a website every hour hoping a pen appears are largely behind us.

But "in stock" is not a single national switch that is either on or off. Availability depends heavily on which strength you need, where you order from, and how a particular pharmacy manages its cold chain. A 2.5mg starter pen is easy to find almost everywhere; a 12.5mg or 15mg maintenance pen can still be patchy in a given week. This article walks through the real picture — which doses are tightest, why supply wobbles at all, how to avoid a gap in your own treatment, and how to stay clear of the counterfeit pens the regulator has warned about.

Is Mounjaro actually in stock right now?

Broadly, yes. The manufacturer, Eli Lilly, has poured billions into new production capacity — including a widely reported multi-billion-dollar expansion of its manufacturing sites — specifically to keep up with demand for tirzepatide (branded Mounjaro for weight management, and Zepbound in the United States). That investment has, by widely reported accounts, translated into meaningfully steadier UK supply through 2025 and into 2026.

The catch is that supply is regional and time-sensitive rather than uniform. A high-street pharmacy runs on a "just-in-time" delivery model: it holds a small amount of stock in a domestic-sized medical fridge and reorders from a wholesaler as it dispenses. When a wholesaler delivery slips by a day or two, that pharmacy shows "out of stock" even though the medicine plainly exists and a clinic a few miles away may have plenty. So you can hit a local, temporary gap while national supply is fundamentally healthy.

It is also worth knowing that private and NHS supply run on separate tracks. NHS access to tirzepatide is being rolled out in phases and is tightly rationed to specific cohorts, managed through its own procurement. If you are a private patient and your provider runs short, you cannot simply top up at an NHS pharmacy — the two systems do not cross over.

Which Mounjaro doses are hardest to find?

Availability is not even across the titration ladder. Understanding the pattern helps you plan.

Mounjaro is designed to be increased gradually. You start at 2.5mg for the first four weeks (this is a starting dose, not a treatment dose), then step up by 2.5mg at intervals of at least four weeks, up to a maximum of 15mg, according to how you tolerate it and respond. Manufacturers naturally produce the lower "entry" strengths in the highest volumes, because every new patient begins there. The higher strengths are made in smaller quantities and involve a more demanding fill-finish stage, so they are the ones most likely to run tight.

The practical takeaway is a "wide entry, narrow exit" supply chain. Getting started is easy; the doses you rely on for maintenance are the ones worth planning around. If a specific maintenance strength is briefly unavailable, the safe move is almost always to hold at your current dose for a little longer rather than to stop — more on that below.

Why does Mounjaro supply wobble at all?

Three things sit behind most short-term gaps, and none of them is the medicine simply not existing.

Global allocation. Lilly supplies tirzepatide worldwide, and the enormous US market influences where batches go first. The UK receives a substantial but finite allocation, so a demand surge in one region can ripple through delivery schedules elsewhere.

The device, not just the drug. The KwikPen is a multi-dose injection device, and manufacturing its precision components is harder than filling a single-dose vial. An updated KwikPen design has been widely reported to be rolling out through 2026 to reduce waste, but device production and the fill-finish stage — where medicine is loaded into pens under strict conditions — remain the real bottlenecks. If one European finishing site slows, UK delivery schedules feel it within days.

Cold chain and storage. Tirzepatide must stay refrigerated from the factory to your door. Community pharmacies have limited fridge space shared with insulin and other temperature-sensitive medicines, so they cannot stockpile hundreds of pens. That is why "we're expecting it tomorrow" can stretch across several days — and why a pharmacy that takes cold-chain integrity seriously will destroy, not sell, any stock that has had a temperature breach.

None of this should alarm you. It simply explains why availability is best thought of as a logistics question with occasional local hiccups, rather than a national crisis.

What to do if your dose is out of stock

If you hit a gap, the single most important principle is: do not stop or improvise on your own. Contact your prescribing clinician as early as you can — ideally a week or two before your current pen runs out — so there is time to plan.

Missing an occasional weekly dose by a day or two is not a disaster; tirzepatide has a long half-life and one late injection will not undo your progress. A longer gap is different. If you go roughly two weeks or more without medication, your tolerance to the drug fades, and jumping straight back onto your previous dose can trigger significant nausea, vomiting and other gastrointestinal effects. In that situation a clinician will usually restart you at a lower dose and re-titrate — which is inconvenient, but far safer. Any side effect you experience, whether when re-titrating or at any other point, can be reported through the MHRA Yellow Card scheme, which helps the regulator monitor medicine safety.

There are a few sensible options a prescriber might discuss:

• Hold at your current dose. If the next strength up is unavailable, staying where you are for an extra month keeps you protected and maintains momentum.
• Bridge with a lower strength temporarily, where clinically appropriate, rather than going without.
• Consider an alternative medicine. If Mounjaro is unavailable for a prolonged period, a clinician may discuss switching to Wegovy (semaglutide). This is a genuine option, not a like-for-like swap — the two drugs act on different receptors, so doses do not translate directly and a fresh assessment is needed to set a safe starting point. Our Mounjaro and Wegovy pages cover the differences, and if injections are the sticking point, the oral semaglutide route is worth a look.

What you should not do is "pharmacy hop" — chasing any available pen across multiple providers without a shared clinical record. That fragments your oversight, raises the risk of dosing errors, and, as the next section explains, walks you toward the part of the market you most want to avoid.

Counterfeit pens: the one supply risk to take seriously

When legitimate stock of a popular strength gets tight, unregulated sellers appear to fill the gap — and this is where a supply inconvenience can become a genuine danger.

In February 2026 the MHRA (the Medicines and Healthcare products Regulatory Agency) issued a specific warning about falsified Mounjaro KwikPen 15mg pens that had entered the UK supply chain via an online pharmacy — a reminder that even the regulated chain can be penetrated by a rogue seller. In that case MHRA testing confirmed the fake pens did contain tirzepatide, but of unverified sterility, and the pharmacy involved has since faced regulatory conditions on its registration. More broadly, falsified injectable products may contain the wrong ingredient, the wrong dose, or non-sterile material that can cause infection — and they bypass every safety check a real pharmacy performs. You can read the specific alert from the MHRA, and if you ever suspect you have received a falsified product or suffered harm, report it through the Yellow Card scheme.

Protecting yourself is straightforward:

• Only use a pharmacy registered with the General Pharmaceutical Council (GPhC). Legitimate providers display their registration and can be checked on the GPhC register.
• Be wary of any seller offering "generic tirzepatide," unbranded vials, or Mounjaro at a price that looks too good to be true. There is no licensed generic tirzepatide in the UK.
• Walk away from anywhere that sells without a consultation. Mounjaro is a prescription-only medicine. It can only be supplied after an online consultation and clinical assessment by a prescriber — never bought off a shelf. A site that skips your medical history is not a pharmacy.

A quick word on safety and eligibility

Because supply questions often come from people new to tirzepatide, it is worth grounding the wider picture.

Mounjaro is licensed in the UK for weight management in adults with a BMI of 30 or more, or a BMI of 27 or more alongside a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. These licensed thresholds are broader than the narrower groups the NHS currently funds. Full details sit in the MHRA guidance for GLP-1 medicines.

On results, the headline figure comes from a named trial, not marketing. In the SURMOUNT-1 trial, adults taking tirzepatide at the 15mg dose lost on average around 22.5% of their body weight over 72 weeks, alongside lifestyle support. That is an average from a controlled study — individual results vary with dose, response and the habits built alongside treatment, so no reputable clinic should quote it as a guarantee.

The most common side effects are gastrointestinal — nausea, diarrhoea, constipation — usually mildest at the start and around dose increases, which is exactly why slow titration matters. Rarer but serious risks deserve real attention. In January 2026 the MHRA strengthened its warnings on acute pancreatitis with GLP-1 and dual GLP-1/GIP medicines; severe, persistent stomach pain that spreads to your back, with nausea or vomiting, is a reason to stop and seek urgent medical help. Gallbladder problems — including gallstones and gallbladder inflammation — can also become more likely with rapid weight loss, and warrant medical attention if you develop upper-right abdominal pain, fever or yellowing of the skin.

Tirzepatide is not for everyone. It should not be used in pregnancy or while breastfeeding, or if you are trying to conceive; it can reduce the effectiveness of the combined oral contraceptive pill, so a barrier method or a switch of contraception may be advised around dose changes. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and a previous episode of pancreatitis is an important reason for caution that your prescriber will weigh carefully. These are precisely the reasons Mounjaro is supplied only after a proper consultation, not off a shelf — a prescriber checks your medical history, current medicines and eligibility before anything is dispensed.

If you experience any side effect, you can report it through the MHRA Yellow Card scheme, which helps the regulator keep monitoring medicine safety. Our fuller write-up on Mounjaro side effects goes into more depth.

How it works at The Weight Clinic

The Weight Clinic is a GPhC-registered UK online pharmacy, and we treat continuity of supply as part of the clinical service rather than an afterthought. In practice that means we prioritise existing patients when we plan our stock, so the pen you need for your next titration step is accounted for before we take on new starts. Our clinicians manage your dose schedule with real supply in mind — if a particular strength looks likely to tighten, the conversation happens before it becomes a problem, not after.

Getting started is simple: complete a free eligibility check and online consultation, and if treatment is appropriate a prescriber assesses you before anything is dispensed. Mounjaro starts from £125 a month, with no subscription lock-in; if you and your clinician decide Wegovy fits better, the first month starts from £80 (£115 standard, with £35 off your first order using code NEWME). You can explore the options on our treatments overview or the weight-loss injections page.

Supply in 2026 is a logistics challenge, not a lottery — and the right way to handle it is a plan, not a scramble. Check your eligibility and let a clinician manage the schedule with you.